Yes if you compare the company progress since the stock hit 8c it is hard to argue that the share price shouldn't be double digits. We are now three quarters through trial recruitment and have credible data to suggest the therapy is working as hoped. If 8c made sense in 2016 then I'd argue the company should be worth at least twice that today.
book, page-57
-
- There are more pages in this discussion • 156 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
